Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis

Journal of managed care & specialty pharmacy

Volumn 23, Issue 3b, 2017, Pages S17-S24

  Fisher, Mark ^a   Nathan, Steven D ^b   Hill, Christian ^a   Marshall, Jade ^a   Dejonckheere, Fred ^c   Thuresson, Per Olof ^c   Maher, Toby M ^d  

^a Falls Church ^*  (United Kingdom)

^b INOVA FAIRFAX HOSPITAL   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPYRONE; NONSTEROID ANTIINFLAMMATORY AGENT; PIRFENIDONE;

ADULT; AGED; CLINICAL TRIAL; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; HUMAN; INTERNATIONAL COOPERATION; LIFE EXPECTANCY; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INTERNATIONALITY; LIFE EXPECTANCY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PYRIDONES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85021860371     PISSN: None     EISSN: 23761032     Source Type: Journal    
DOI: 10.18553/jmcp.2017.23.3-b.s17     Document Type: Article

References (0)